An Exploratory Study to Evaluate the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine With Sintilimab and Donafenib for Unresectable Hepatocellular Carcinoma
This is a single-arm exploratory clinical study to evaluate the efficacy and safety of HAIC in combination with Sintilimab and Donafenib in patients with BCLC-C stage who have not received prior systemic therapy
• Written informed consent should be signed before implementing any trial-related procedures
• ECOG PS scores 0-1
• Histologically/cytologically confirmed HCC or cirrhosis meeting the clinical diagnostic criteria of HCC by American Association for the Study of Liver Diseases (AASLD)
• Barcelona Clinic Liver Cancer (BCLC) stage C
• Newly diagnosed HHC patients without any previous treatment for the tumor
• Child Pugh score of ≤ 7.
• Estimated survival \> 12 weeks
• At least one measurable lesion according to RECIST V1.1
• Sufficient organ and bone marrow functions